Literature DB >> 26511623

Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants.

Kevin Blauth1, John Soltys1,2, Adeline Matschulat1, Cory R Reiter1, Alanna Ritchie1, Nicholas L Baird1, Jeffrey L Bennett1,2,3, Gregory P Owens4.   

Abstract

B cells are implicated in the etiology of multiple sclerosis (MS). Intrathecal IgG synthesis, cerebrospinal fluid (CSF) oligoclonal bands and lesional IgG deposition suggest a role for antibody-mediated pathology. We examined the binding of IgG1 monoclonal recombinant antibodies (rAbs) derived from MS patient CSF expanded B cell clones to central nervous system (CNS) tissue. MS rAbs displaying CNS binding to mouse and human CNS tissue were further tested for their ability to induce complement-mediated tissue injury in ex vivo spinal cord explant cultures. The staining of CNS tissue, primary human astrocytes and human neurons revealed a measurable bias in MS rAb binding to antigens preferentially expressed on astrocytes and neurons. MS rAbs that recognize myelin-enriched antigens were rarely detected. Both myelin-specific and some astrocyte/neuronal-specific MS rAbs caused significant myelin loss and astrocyte activation when applied to spinal cord explant cultures in the presence of complement. Overall, the intrathecal B cell response in multiple sclerosis binds to both glial and neuronal targets and produces demyelination in spinal cord explant cultures implicating intrathecal IgG in MS pathogenesis.

Entities:  

Keywords:  Autoimmunity; Demyelination; Monoclonal antibody; Multiple sclerosis; Neuroimmunology; Spinal cord slice cultures

Mesh:

Substances:

Year:  2015        PMID: 26511623      PMCID: PMC4655138          DOI: 10.1007/s00401-015-1500-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  32 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  Analysis of multiple sclerosis cerebrospinal fluid reveals a continuum of clonally related antibody-secreting cells that are predominantly plasma blasts.

Authors:  Kimberly M Winges; Donald H Gilden; Jeffrey L Bennett; Xiaoli Yu; Alanna M Ritchie; Gregory P Owens
Journal:  J Neuroimmunol       Date:  2007-11-13       Impact factor: 3.478

3.  CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome.

Authors:  Jeffrey L Bennett; Kurt Haubold; Alanna M Ritchie; Sydni J Edwards; Mark Burgoon; Andrew J Shearer; Donald H Gilden; Gregory P Owens
Journal:  J Neuroimmunol       Date:  2008-06-10       Impact factor: 3.478

4.  Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis.

Authors:  Birgit Obermeier; Reinhard Mentele; Joachim Malotka; Josef Kellermann; Tania Kümpfel; Hartmut Wekerle; Friedrich Lottspeich; Reinhard Hohlfeld; Klaus Dornmair
Journal:  Nat Med       Date:  2008-05-18       Impact factor: 53.440

5.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

6.  B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions.

Authors:  S E Baranzini; M C Jeong; C Butunoi; R S Murray; C C Bernard; J R Oksenberg
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

7.  Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis.

Authors:  S Cepok; M Jacobsen; S Schock; B Omer; S Jaekel; I Böddeker; W H Oertel; N Sommer; B Hemmer
Journal:  Brain       Date:  2001-11       Impact factor: 13.501

8.  Homogeneity of active demyelinating lesions in established multiple sclerosis.

Authors:  Esther C W Breij; Bianca P Brink; Rob Veerhuis; Christa van den Berg; Rianka Vloet; Riqiang Yan; Christine D Dijkstra; Paul van der Valk; Lars Bö
Journal:  Ann Neurol       Date:  2008-01       Impact factor: 10.422

9.  Oligoclonal immunoglobulins in cerebrospinal fluid during varicella zoster virus (VZV) vasculopathy are directed against VZV.

Authors:  Mark P Burgoon; Barbara N Hammack; Gregory P Owens; Amy L Maybach; M Judith Eikelenboom; Donald H Gilden
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

10.  Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis.

Authors:  Christina Elliott; Maren Lindner; Ariel Arthur; Kathryn Brennan; Sven Jarius; John Hussey; Andrew Chan; Anke Stroet; Tomas Olsson; Hugh Willison; Susan C Barnett; Edgar Meinl; Christopher Linington
Journal:  Brain       Date:  2012-05-04       Impact factor: 13.501

View more
  35 in total

1.  Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Authors:  Jacqueline R Rivas; Sara J Ireland; Rati Chkheidze; William H Rounds; Joseph Lim; Jordan Johnson; Denise M O Ramirez; Ann J Ligocki; Ding Chen; Alyssa A Guzman; Mark Woodhall; Patrick C Wilson; Eric Meffre; Charles White; Benjamin M Greenberg; Patrick Waters; Lindsay G Cowell; Ann M Stowe; Nancy L Monson
Journal:  Acta Neuropathol       Date:  2016-10-11       Impact factor: 17.088

2.  Antibodies in multiple sclerosis oligoclonal bands target debris.

Authors:  Ryan C Winger; Scott S Zamvil
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-28       Impact factor: 11.205

Review 3.  B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.

Authors:  Silke Kinzel; Martin S Weber
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

4.  Leptomeningeal Enhancement at 7T in Multiple Sclerosis: Frequency, Morphology, and Relationship to Cortical Volume.

Authors:  Daniel M Harrison; Kevin Y Wang; Julie Fiol; Kerry Naunton; Walter Royal; Jun Hua; Izlem Izbudak
Journal:  J Neuroimaging       Date:  2017-05-02       Impact factor: 2.486

Review 5.  Multiple Sclerosis Pathology.

Authors:  Hans Lassmann
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

6.  Experimental laboratory biomarkers in multiple sclerosis.

Authors:  Borros Arneth; Jörg Kraus
Journal:  Wien Med Wochenschr       Date:  2022-03-07

Review 7.  Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.

Authors:  Romana Höftberger; Hans Lassmann; Thomas Berger; Markus Reindl
Journal:  Nat Rev Neurol       Date:  2022-08-15       Impact factor: 44.711

Review 8.  The role of B cells in the immunopathogenesis of multiple sclerosis.

Authors:  Tohid Gharibi; Zohreh Babaloo; Arezoo Hosseini; Faroogh Marofi; Abbas Ebrahimi-Kalan; Saeed Jahandideh; Behzad Baradaran
Journal:  Immunology       Date:  2020-05-10       Impact factor: 7.397

9.  Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance.

Authors:  Simon Glatigny; Barbara Höllbacher; Samantha J Motley; Cathy Tan; Christian Hundhausen; Jane H Buckner; Dawn Smilek; Samia J Khoury; Linna Ding; Tielin Qin; Jorge Pardo; Gerald T Nepom; Laurence A Turka; Kristina M Harris; Daniel J Campbell; Estelle Bettelli
Journal:  J Immunol       Date:  2019-01-25       Impact factor: 5.422

Review 10.  B cells in autoimmune and neurodegenerative central nervous system diseases.

Authors:  Joseph J Sabatino; Anne-Katrin Pröbstel; Scott S Zamvil
Journal:  Nat Rev Neurosci       Date:  2019-11-11       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.